Cara Therapeutics Inc (CARA)

15.05 -0.11  -0.73% NASDAQ Nov 25, 20:00 USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/26/2021 Earnings Cara Therapeutics Inc Fourth Quarter Earnings for 2020 Release
02/26/2021 Misc Cara Therapeutics Inc Fourth Quarter Earnings Conference Call for 2020
11/09/2020 Earnings Cara Therapeutics Inc Third Quarter Earnings Result for 2020
11/09/2020 16:30 EST Misc Cara Therapeutics Inc Third Quarter Earnings Conference Call for 2020
08/10/2020 16:30 EDT Misc Cara Therapeutics Inc Second Quarter Earnings Conference Call for 2020
08/10/2020 Earnings Cara Therapeutics Inc Second Quarter Earnings Result for 2020
06/04/2020 11:00 EDT Misc Cara Therapeutics Inc Annual General Meeting for 2019
05/11/2020 16:30 EDT Misc Cara Therapeutics Inc First Quarter Earnings Conference Call for 2020
05/11/2020 Earnings Cara Therapeutics Inc First Quarter Earnings Result for 2020
02/27/2020 16:30 EST Misc Cara Therapeutics Inc Fourth Quarter Earnings Conference Call for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.caratherapeutics.com
  • Investor Relations URL: http://ir.caratherapeutics.com/
  • HQ State/Province: Connecticut
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: Feb. 26, 2021
  • Last Earnings Release: Nov. 09, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Top Fund Holders

Symbol Name Weighting
CNBS Amplify Seymour Cannabis ETF 2.13%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.